

Medicare Advantage Medical Policy



Nonprofit corporations and independent licensees
of the Blue Cross and Blue Shield Association

Dual Energy X-Ray Absorptiometry (DXA) and Bioelectrical Impedance Analysis (BIA) to Determine Body Composition – Medicare Advantage

Medicare Advantage Plan

- ☒ Medicare Plus BlueSM
- ☒ BCN AdvantageSM

UM Committee Approval Date: 03/19/2025

Effective Date: 04/19/2025

Description

Dual energy x-ray absorptiometry (DXA) is proposed to be able to determine body composition by using x-rays at two different energy levels to differentiate among bone, fat mass, and lean body mass. Bioelectrical impedance analysis (BIA) is another proposed method for estimating body composition, particularly body fat percentage and lean body mass. It works by sending a small electrical current through the body and measuring the resistance (impedance) to that current. Water and electrolytes in lean tissue conduct electricity well, whereas fat does not, allowing the device to estimate the proportions of fat mass and lean mass.

Related Medical Coverage Policies

- N/A

Policy Guidelines

Blue Cross Blue Shield of Michigan (BCBSM) and Blue Care Network of Michigan (BCN) adhere to guidance from the Centers for Medicare and Medicaid Services (CMS), including when performing organization determinations for Medicare Advantage plan members. CMS Medicare statutes, regulations, manuals, National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), Local Coverage Articles (LCAs) and other sub-regulatory guidance provide the clinical guidelines for coverage determinations, payment integrity functions, and all other uses by CMS regulations. When CMS Medicare guidance is not fully established, CMS permits BCBSM/BCN to utilize “internal coverage criteria”, such as independent criteria, health plan policy research, LCD/LCAs outside the services area or research from independent medical research repositories (i.e., Hayes) for coverage policies 42 CFR § 422.101. BCBSM/BCN internal medical coverage policies are developed and based on current evidence in widely accepted treatment guidelines or clinical literature; in addition, they address how clinical benefits may or may not outweigh member harm.

The following is applicable for this medical policy:

After searching the Medicare Coverage Database and other sources of conditions of coverage, it was determined that CMS guidance is not fully developed, related to codes found in this medical policy. BCBSM/BCN internal policy coverage criteria will be applied.

Code	Description	NCD/LCD/LCA	Additional Guidance
76499	Unlisted diagnostic radiographic procedure [as it relates to DXA and BIA to determine body composition]	None	When the NCD or LCDs/LCAs does not have fully established clinical coverage criteria to determine medical necessity for DXA and BIA to determine body composition refer to the BCBSM/BCN policy: <i>Dual Energy X-Ray Absorptiometry (DXA) and Bioelectrical Impedance Analysis (BIA) to Determine Body Composition</i> Policy attached below
0358T	Bioelectrical impedance analysis whole body composition assessment, with interpretation and report.		

CPT® codes, descriptions and materials are copyrighted by the American Medical Association (AMA).

HCPCS® codes, descriptions and materials are copyrighted by Centers for Medicare and Medicaid Services (CMS).

The above information is current as of the review date for this policy. However, the coverage issues and policies maintained by CMS are updated and/or revised periodically. Therefore, the most current CMS information may not be contained in this document. Please refer to the Medicare Coverage Database website at <https://www.cms.gov/medicare-coverage-database/search.aspx> for the most current applicable NCD, LCD, LCA, and CMS Online Manual System Transmittals.

CMS Medicare Administrative Contractors (MAC) Jurisdictions

Part A and Part B Medicare Administrative Contractor (MAC) Jurisdiction	
Wisconsin Physicians Service Insurance Corporation (WPS)	IA, IN, KS, MI, MO, NE
CGS Administrators, LLC	KY, OH
First Coast Service Options, Inc	FL, PR, US VI
National Government Services, Inc (NGS)	CT, IL, MA, ME, MN, NH, NY, RI, VT, WI,
Noridian Healthcare Solutions, LLC, Jurisdiction JE	CA, HI, NV, American Samoa, Guam, Northern Mariana Islands
Noridian Healthcare Solutions, LLC, Jurisdiction JF	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
Novitas Solutions, Inc	AR, CO, DC, DE, LA, MD, MS, NJ, NM, OK, PA, TX,
Palmetto GBA	AL, GA, TN NC, SC, VA, WV
DME MAC Jurisdictions	
CGS Administrators, LLC, Jurisdictions JB and JC	AL, AR, CO, FL, GA, IL, IN, KY, LA, MI, MN, MS, NM, NC, OH, OK, Puerto Rico, SC, TN, TX, VA, Virgin Island, WI, WV
Noridian Healthcare Solutions, LLC, Jurisdictions JA and JD	AK, American Soamoa, AZ, CA, CT, DE, DC, Guam, HI, ID, IA, KS, MA, MD, ME, MO, MT, ND, NE, NH, NJ, NV, NY, Northern Mariana Islands, OR, PA, RI, SD, UT, VT, WA, WY

Important Reminder

BCBSM and BCN follow CMS Medicare coverage guidance to limit coverage to items and services that are reasonable and necessary for the diagnosis or treatment of an illness or injury or to improve the functioning of a malformed body member. Medicare Advantage Medical Policies list the criteria BCBSM and BCN use to decide which medical services are considered “reasonable and necessary” when Medicare coverage rules are not fully

developed, or as otherwise may permitted by CMS Medicare regulations. Individual member benefit plan documents, such as the Evidence of Coverage and Annual Notice of Change, as well as applicable laws govern benefit coverage, including any inclusion, exclusion, and/or other restrictions.

Medicare Advantage Medical policies are created when permitted by CMS Medicare regulations, reviewed regularly, and may be revised periodically. BCBSM/BCN Medical Policies are proprietary and should not be copied or disseminated without the express, prior written approval of BCBSM. All providers are required to review applicable BCBSM reimbursement policies prior to claim submission and bill for covered services in accordance with those policies. Additionally, providers contracted with BCBSM or BCN’s Medicare Advantage network(s) should review the provider manual for any additional claim submission requirements. Providers not contracted with BCBSM or BCN’s Medicare Advantage network may be required to submit documentation to BCBSM, BCN, or its delegated entity supporting billed claims, including but not limited to applicable medical records.

Note: U.S. Food and Drug Administration (FDA) approval for a specific indication or the issuance of a CPT code is not sufficient for a procedure to be considered medically reasonable and necessary. Similarly, the presence of a procedure/device code or payment amount for the service in the Medicare fee schedule does not necessarily indicate coverage. If a service is deemed not reasonable and necessary, to treat illness or injury for any reason (including lack of safety and efficacy because it is an experimental procedure, etc.), the procedure is considered not covered.

Disclaimer: This medical policy is not an authorization, certification, explanation of benefits, or a contract for the services, devices, or drugs that is referenced in the medical policy. Medical policies do not constitute medical advice and do not guarantee any results or outcomes or guarantee payment. The medical policy is not intended to replace independent medical judgment for treatment of individuals. Treating physicians and health care providers are solely responsible for determining what care to provide to their patients. Identification of selected brand names of devices, tests and procedures in a medical coverage policy is for reference only and is not an endorsement of any one device, test, or procedure over another.

Pursuant to Section 1557 and Section 504, Blue Cross does not discriminate on the basis of race, color, national origin, age, disability, or sex (including sex characteristics, intersex traits; pregnancy or related conditions; sexual orientation; gender identity, and sex stereotypes). This includes our rules, benefit designs and medical policies.

BCBSM/BCN Medicare Advantage Policy History

Policy Effective Date	UM Committee Approval Date	Comments
07/17/2024	07/17/2024	Medicare Advantage policy established
04/19/2025	03/19/2025	MA policy foundational language updated. Adoption of JUMP policy updates.

Medical Policy



Nonprofit corporations and independent licensees
of the Blue Cross and Blue Shield Association

Joint Medical Policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. Please reference the appropriate certificate or contract for benefit information. This policy may be updated and is therefore subject to change.

***Current Policy Effective Date: 3/1/25**
(See policy history boxes for previous effective dates)

Title: Dual Energy X-Ray Absorptiometry (DXA) and Bioelectrical Impedance Analysis (BIA) to Determine Body Composition

Description/Background

BODY COMPOSITION MEASUREMENT

Body composition measurements can be used to determine the relative proportions of specific body components, usually fat versus lean body mass (ice, muscle, bone, organ tissue)¹. These measurements may be more precise than standard non-specific assessments such as weight and body mass index (BMI). While these body composition measurements have been most frequently used for research, they may be useful in clinical settings to:

- Evaluate the health status of undernourished patients, those impacted by certain disease states (ego, anorexia nervosa, cachexia), or those undergoing certain treatments (eg, antiretroviral therapy, bariatric surgery).
- Predict the risk of heart disease or diabetes by measuring visceral fat versus total body fat.
- Monitor body composition changes during growth and development (eg, infancy, childhood), aging (eg, sarcopenia), and certain disease states (eg, HIV, diabetes).
- Evaluate patients in whom BMI may be discordant with total fatty tissue mass (eg, body-building, edema).

Various techniques have been used for body composition measurement, including most commonly, anthropomorphic measures, bioelectrical impedance, and dual energy x-ray absorptiometry (DXA). All of these techniques are based in part on assumptions about the distribution of different body compartments and their density, and all rely on formulas to convert the measured parameter into an estimate of body composition. Therefore, they will vary depending on their underlying assumptions and how those assumptions apply to different populations (ie, different age groups, ethnicities, or underlying conditions). The techniques of anthropomorphics, bioelectrical impedance, underwater weighing, and DXA are briefly reviewed below.

Anthropomorphic Measurement

Anthropomorphic techniques for the estimation of body composition include measurements of skinfold thickness at various sites, bone dimensions, and limb circumference.^{1,2} These measurements are used in various equations to predict body density and body fat. Due to its ease of use, measurement of skinfold thickness is 1 of the most common techniques. The technique is based on the assumption that the subcutaneous adipose layer reflects total body fat, even though this association may vary with age and sex. Skinfold thickness measurement precision and utility can also be affected by operator experience and a lack of applicable reference data for specific patient populations or percentile extremes.

Bioelectrical Impedance

Bioelectrical impedance analysis is based on the relation between among the volume of the conductor (ie, human body), the conductor's length (ie, height), the components of the conductor (ie, fat and fat-free mass), and its impedance.^{1,2} The technique involves attaching surface electrodes to various locations on the arm and foot. Alternatively, the patient can stand on pad electrodes.

Estimates of body composition are based on the assumption that the overall conductivity of the human body is closely related to lean tissue. The impedance value is then combined with anthropomorphic data and certain other patient-specific parameters (eg, age, gender, ethnicity) to give body compartment measures. These measures are calculated based on device manufacturer-specific regression models, which are generally proprietary. Bioelectrical impedance measures can be affected by fat distribution patterns, hydration status, ovulation, and temperature.

Underwater Weighing

Underwater weighing requires the use of a specially constructed tank in which the subject is suspended on a chair.¹ The subject is submerged in the water while exhaling; the difference between weight in air and weight in water is used to estimate total body fat percentage. This technique is based, on the assumption that the body can be divided into 2 compartments with constant densities: adipose tissue, which has a density of 0.9 g/cm³, and lean body mass (ie, muscle and bone), with a density of 1.1 g/cm³. One limitation of the underlying assumption is the variability in density between muscle and bone; bone has a higher density than muscle, and bone mineral density varies with age and other conditions. The density of body fat may vary as well, depending on its relative constituents (eg, glycerides, sterols, glycolipids). While valued as a research tool, underwater weighing is typically not suitable for routine clinical use.

Dual-energy X-Ray Absorptiometry

While the techniques cited above measure two body components, DXA can estimate three body components: fat mass, lean body mass, and bone mass.^{1,2} DXA systems use a source that generates x-rays at two energies. The differential attenuation of the two energies is used to estimate the bone mineral content and soft tissue composition. When two x-ray energies are used, only two tissue compartments can be measured; therefore, soft tissue measurements (ie, fat and lean body mass) can only be measured in areas in which no bone is present. DXA can also determine body composition in defined regions (ie, the arms, legs, and trunk). DXA measurements are based in part on the assumption that the hydration of fat-free mass remains constant at 73%. Hydration, however, can vary from 67% to 85% and can vary by disease state. Other assumptions used to derive body composition estimates are considered proprietary by DXA manufacturers.

Regulatory Status

Body composition software for several bone densitometer systems have been approved by the U.S. Food and Drug Administration (FDA) through the premarket approval process. They include the Lunar iDXA systems (GE Healthcare), Hologic DXA systems (Hologic), Mindways Software, Inc. Systems (Mindways Software, Inc.) and Norland DXA systems (Swissray).
FDA product code: KGI.

Several body composition analyzers that use bioelectrical impedance analysis have been approved by the FDA through the premarket approval process. They include the BC1 Body Composition Analyzer (Stayhealthy Inc.) and the Bodystat 1500 Body Composition Monitoring Unit (Bodystat LTD).
FDA product code MNW.

Medical Policy Statement

The DXA body composition system is considered **experimental/investigational**. While it may be safe, its utility in the medical management of the patient compared to standard currently available measurement methods has not been scientifically determined.

Bioelectrical impedance for body composition analysis is considered **experimental/investigational**. It has not been scientifically demonstrated to be an accurate and useful diagnostic tool.

Inclusionary and Exclusionary Guidelines

N/A

CPT/HCPCS Level II Codes *(Note: The inclusion of a code in this list is not a guarantee of coverage. Please refer to the medical policy statement to determine the status of a given procedure.)*

Established codes:

N/A

Other codes (investigational, not medically necessary, etc.):

76499

0358T

Rationale

Evidence reviews assess whether a medical test is clinically useful. A useful test provides information to make a clinical management decision that improves the net health outcome. That is, the balance of benefits and harms is better when the test is used to manage the condition than when another test or no test is used to manage the condition.

The first step in assessing a medical test is to formulate the clinical context and purpose of the test. The test must be technically reliable, clinically valid, and clinically useful for that purpose. Evidence reviews assess the evidence on whether a test is clinically valid and clinically useful.

Technical reliability is outside the scope of these reviews, and credible information on technical reliability is available from other sources.

DUAL-ENERGY X-RAY ABSORPTIOMETRY AS A TEST TO DETECT ABNORMAL BODY COMPOSITION

Clinical Context and Test Purpose

The purpose of dual-energy x-ray absorptiometry (DXA) body composition studies is to improve the diagnosis and management of individuals who have a clinical condition associated with an abnormal body composition.

The following PICO was used to select literature to inform this review.

Populations

The relevant population of interest is individuals with clinical conditions associated with abnormal body composition.

Interventions

The test being considered is DXA body composition studies.

Comparators

The following practices are currently being used to make decisions in this group: standard of care without DXA or an alternative method of body composition analysis.

Outcomes

The general outcomes of interest include symptom management and change in disease status. For individuals with human immunodeficiency virus (HIV) who are treated with antiretroviral therapy, outcomes of interest would include lipodystrophy.

Study Selection Criteria

For the evaluation of clinical validity of DXA body composition testing, studies that meet the following eligibility criteria were considered:

- Reported on the accuracy of the marketed version of the technology (including any algorithms used to calculate scores)
- Included a suitable reference standard
- Patient/sample clinical characteristics were described
- Patient/sample selection criteria were described.

Clinically Valid

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

REVIEW OF EVIDENCE

Systematic Reviews

A systematic review and meta-analysis comparing the accuracy of alternative comparators versus reference standard computed tomography (CT) and magnetic resonance imaging (MRI) methods for the quantification of intra-abdominal adipose tissue (IAAT) was published by Murphy et al (2019).³ This systematic review assessed the performance of DXA for IAAT volume quantification and compared the performance of both DXA and bioelectric

impedance analysis (BIA) approaches for IAAT area quantification. The American Society for Parenteral and Enteral Nutrition (ASPEN) also conducted a systematic review to evaluate the validity of relevant body composition methods in various clinical populations.⁴ The use of DXA, ultrasound, and BIA for body composition analysis was investigated. Fifteen studies featuring comparisons of DXA to reference standard methods (eg, MRI and CT) were identified. Nine studies using CT or MRI to validate DXA measures of abdominal fat mass (FM) or total body FM were used for pooled analyses. Characteristics and results of these meta-analyses are summarized in Tables 1 and 2.

Table 1. Systematic Review & Meta-Analysis Characteristics

Study; Subgroup	Dates	Trials	Participants ¹	N (Range)	Design	Duration
Murphy et al (2019) ³	1995- 2018	23	Studies: • With IAAT quantified in humans by CT or MRI reference methods and 1 of DXA, ultrasound, BIA, or air displacement plethysmography • With reference and comparator methods that quantify IAAT at the same anatomical location in the same unit of measurement • With reported or quantifiable mean differences and SDs of IAAT quantity	6116 to (29-2689)	Cross-sectional, diagnostic test accuracy studies Retrospective studies	NR
IAAT Area						
DXA	2012- 2014	3	Included population groups: • Elderly adult men and women evaluated by DXA and CT at L4 to L5 • Premenopausal women evaluated by DXA and CT at L4 to L5 • Premenopausal women evaluated by DXA and CT at L4	381 to (115-135)	Cross-sectional, diagnostic test accuracy studies Retrospective studies	NR
BIA	2008- 2018	9*	Included population groups: • Elderly Caucasian men and women evaluated by BIA and CT at L3 to L4 • Elderly Korean adult men and women evaluated by BIA and CT at umbilicus • Elderly Korean adult men and women evaluated by BIA and CT at L4 to L5 • Japanese outpatients with obesity evaluated by BIA and CT at umbilicus • Elderly, middle-aged, and adult Chinese men and women evaluated by BIA and CT at L4-L5 • Elderly adult men and women evaluated by BIA and MRI at L4 to L5 • Elderly, middle-aged, adult, and young men and women evaluated by BIA and CT at L4 to L5	2139 to (100-1006)	Cross-sectional, diagnostic test accuracy studies Retrospective studies	NR
IATT Volume						
DXA	2012- 2018	7**	Included population groups: • Adult men and women evaluated by DXA and CT from S1 to head region • Elderly adult men and women evaluated by DXA and CT from S1 to head region • Women with PCOS evaluated by DXA and MRI at L3 • Middle-Eastern adult men and women evaluated by DXA and MRI at android region • Adult men and women evaluated by DXA and MRI at L2 to L3 with conversion to L1 through L5	3410 to (40-2689)	Cross-sectional, diagnostic test accuracy studies Retrospective studies	NR
IATT Thickness						
US	2010- 2014	4	Included population groups: • Obese women with infertility evaluated by US and CT at L4 to L5	186 to (29-74)	Cross-sectional, diagnostic test accuracy studies	NR

			• Middle-aged men and women evaluated by US and CT at L2 to L3 • Elderly and adult men and women evaluated by US and MRI at L2 to L3 • Elderly men and women evaluated by US and MRI at L4		Retrospective studies	
Sheean et al (2019) ⁴ (ASPEN)	2001-2013	9	Studies: • With body compositions assessed in clinical populations via DXA and a reference standard method (eg, MRI or CT) • With correlation analyses	1660 to (39-625)	Cross-sectional, diagnostic test accuracy studies Retrospective studies	NR
Abdominal FM in any disease via DXA	2004-2013	4	Included population groups: • Urban Asian Indians with type 2 diabetes • Premenopausal women with anorexia nervosa • Middle-aged Indian men with CVD • Multiethnic cohort of men and women with HIV	874 to (39-625)	Cross-sectional, diagnostic test accuracy studies Retrospective studies	NR
Total FM in any disease via DXA	2001-2013	7	Included population groups: • Women with CVD • Postmenopausal women with CVD • Men and women with CVD • Middle-aged Indian men with CVD • Individuals with myosteatosis • Multiethnic cohort of men and women with HIV	1473 to (66-625)	Cross-sectional, diagnostic test accuracy studies Retrospective studies	NR
Total FM in CVD via DXA	2001-2013	5	Included population groups: • Men and women with CVD • Postmenopausal women with CVD • Middle-aged Indian men with CVD	521 to (66-132)	Cross-sectional, diagnostic test accuracy studies Retrospective studies	NR

ASPEN: American Society for Parenteral and Enteral Nutrition; BIA: bioelectrical impedance analysis; CT: computed tomography; CVD: cardiovascular disease; DXA: dual-energy x-ray absorptiometry; FM: fat mass; HIV: human immunodeficiency virus; IAAT: intra-abdominal adipose tissue; MRI: magnetic resonance imaging; NR: not reported; PCOS: polycystic ovarian syndrome; SD: standard deviation; US: ultrasound.

¹ Key study eligibility criteria and demographics of included subgroup participants.

* 3 of 9 trials were sampled twice for a total of 12 result sets due to use of multiple techniques for IAAT quantification via BIA.

** one of eight trials was categorized as an outlier and excluded from pooled analysis.

Table 2. Systematic Review & Meta-Analysis Results

Study	Mean Difference in IAAT Volume	Mean Difference in IAAT Area		Mean Difference in IAAT Thickness
Murphy et al (2019) ³	DXA*	DXA	BIA	US
Total N	3410	381	2139	186
Pooled mean difference (95% LoA)	-10 (-280 to 300) (cm ³)	8.09 (-98.88 to 115.07) (cm ²)	-11.63 (-43.12 to 19.85) (cm ²)	-0.32 (-3.82 to 3.17) (cm)
Significance of mean difference (p)	.808	.061	.004	.400
I ² (p)	99% (<0.001)	98% (<0.001)	94% (<0.001)	93% (<0.001)
Q	Q ₍₆₎ = 458	Q ₍₂₎ = 31	Q ₍₁₁₎ = 544	Q ₍₃₎ = 41
Range of N	40 to 2689	115 to 135	100 to 1006	29 to 74
Range of pooled mean differences	(-451 to 262) (cm ³)	(3.78 to 16.70) (cm ²)	(-57.20 to 10.96) (cm ²)	(-1.10 to 0.40) (cm)
DXA Subgroup Analysis	Mean Difference in IAAT Volume by DXA and Gender		Mean Difference in IAAT Volume by DXA and Reference Method	
Subgroup	Men	Women	CT	MRI
Subgroup N (Total N)	1483 (3287)	1804 (3287)	377 (3410)	3033 (3410)
Pooled mean difference (95% LoA) (cm ³)	144.04 (-512.29 to 800.38)	59.96 (-381.08 to 492.99)	-41.15 (-881.96 to 930.25)	49.52 (-498.42 to 586.23)
Significance for subgroup comparison (p)	.042		.311	
I ²	95%	90%	100%	90%
Range of Subgroup N	20 to 1212	20 to 1477	109 to 145	40 to 2689
Range of pooled mean differences (cm ³)	-43 to 379	4 to 143	451 to 262	4 to 104
Sheean et al (2019) ⁴ (ASPEN)	DXA-derived Abdominal FM	DXA-derived Total FM		
	DXA vs CT-derived VAT in any disease	DXA vs CT/MRI-derived VAT in any disease	DXA vs CT/MRI-derived VAT in CVD	
Total N	874	1473	521	
Pooled random effects correlation (95% CI)	0.74 (0.52 to 0.86)	0.71 (0.45 to 0.86)	0.71 (0.45 to 0.84)	
I ² (p)	87% (<0.01)	98% (<0.01)	95% (<0.01)	
Range of N	39 to 625	66 to 625	66 to 132	
Range of individual correlations	0.52 to 0.86	0.49 to 0.80	0.49 to 0.87	

ASPEN: American Society for Parenteral and Enteral Nutrition; BIA: bioelectrical impedance analysis; CI: confidence interval; CT: computed tomography; CVD: cardiovascular disease; DXA: dual-energy x-ray absorptiometry; FM: fat mass; IAAT: intra-abdominal adipose tissue; LoA: limits of agreement; M-A: meta-analysis; MRI: magnetic resonance imaging; SR: systematic review; US: ultrasound; VAT: visceral adipose tissue.

Because the analysis by Murphy et al (2019)³ aimed to evaluate agreement between DXA and CT or MRI, direct effects on key health outcomes were not explored and patient populations included for analysis displayed extensive heterogeneity and largely featured healthy populations. Measurements of IAAT volume via DXA were deemed comparable to the reference methods, however, 95% limits of agreement (LoA) were wide and these results were not seen until the removal of an outlying study. Performance of DXA for the measurement of IAAT volume also varied significantly between male and female subgroups. Furthermore, included studies did not pre-determine clinically meaningful LoA. The authors' further caution that DXA measurement of IAAT volume has the capacity to differ from reference methods by more than 100%, however, the clinical significance of these margins of error are uncertain in individuals with obesity. While IAAT area cutoff points have been described for the determination of metabolic risk and visceral obesity based on single-slice CT computed tomography, the authors do not recommend utilization of DXA IAAT area measurements for this purpose due to wide LoA. The clinical utility of existing IAAT area cut points is also uncertain as these parameters were found to have applicability for women and cannot necessarily be extrapolated to mixed populations.

Calella et al (2019) performed a systematic review exploring various methods for body composition analysis in patients with cystic fibrosis (CF).⁵ A previous systematic review by Calella et al (2018) presented on differences in body composition between patients with CF cystic fibrosis and healthy controls evaluated by DXA and other methods.⁶ DXA was most frequently used to measure lean body or fat-free mass (FFM) which was significantly reduced in CF patients. While several included studies showed a correlation between lower fat-free mass FFM and impaired pulmonary function, and use of this measure in patient management and its impact on health outcomes was not explored and requires further clarification. As these reviews featured qualitative analyses, data on clinical validity could not be extracted.

A systematic review by Bundred et al (2019) evaluated body composition assessment and sarcopenia in patients with pancreatic ductal adenocarcinoma.⁷ Meta-analyses revealed that sarcopenia was associated with lower overall survival in both operable (hazards ratio: 1.95; 95% confidence interval [CI], 1.35-2.81; $p < .001$) and unresectable patients (hazards ratio: 2.49; 95% CI, 1.38-4.48; $p = .002$). However, of the 42 included studies, only one utilized measurements obtained by DXA, limiting the relevance of the overall findings to this technology and preventing extraction of pertinent clinical validity data. Furthermore, the authors caution that many studies failed to account for variation introduced by gender, race, tumor stage, and other factors. Additionally, clear criteria for the diagnosis of sarcopenia or cachexia via body composition assessments with DXA are lacking.

Cross-Sectional Studies

Most of the literature on DXA as a diagnostic test to detect abnormal body composition involves the use of the technology in the research setting, often as a reference test; studies have been conducted in different populations of patients and underlying disorders.⁸⁻²³ In some cases, studies compare other techniques with DXA to identify simpler methods of determining body composition. In general, these studies have shown that DXA is highly correlated to various methods of body composition assessment. For example, a study by Alves et al (2014) compared two bioelectrical impedance devices with DXA for the evaluation of body composition in heart failure.⁸ Ziai et al (2014) compared bioelectric impedance analysis with DXA for evaluating body composition in adults with CF.⁹ The literature on DXA in population-based cohorts (eg, National Health and Nutrition Examination Survey [NHANES], Prospective Epidemiological Risk Factor Study)^{24,25} involves the use of the technology to predict risk of

overall mortality or cancer incidence. These studies often use DXA as a reference test to assess whether agreement with anthropometric measures (eg, body mass index [BMI], relative fat mass [RFM]) is present²⁴ or absent.²⁵ Whether or not a DXA scan is considered the reference standard, the key consideration regarding its routine clinical use is whether the results of the scan can be used to manage the patients and improve health outcomes.

Case-Control Studies

As a single diagnostic measure, it is important to establish diagnostic cutoff points for normal and abnormal values. This is problematic because normal values will require the development of normative databases for the different components of body composition (ie, bone, fat, lean mass) for different populations of patients at different ages. Regarding measuring bone mineral density (BMD), normative databases have largely focused on postmenopausal White women, and these values cannot necessarily be extrapolated to men or to different races. DXA determinations of BMD are primarily used for fracture risk assessment in postmenopausal women and to select candidates for various pharmacologic therapies to reduce fracture risk. Uncertainties of establishing normal values for other components of body composition, it also is unclear how a single measure of body composition would be used in patient management. In an example regarding lean mass, Reina et al (2019) conducted a case-control study to assess the correlation of BMI or serum albumin levels to DXA-derived parameters of nutritional status and sarcopenia in women (n=89) with rheumatoid arthritis (RA).²⁶ While 44% of cases met diagnostic criteria for sarcopenia based on quantification of the skeletal muscle index, a reference technique was not clearly identified in this study. Skeletal muscle index MI is calculated by dividing appendicular skeletal muscle mass by the square of the patient's height. A previously identified threshold of ≤ 5.75 kg/m² in women was applied, however, this metric was established through the use of BIA in a slightly older patient population. Given that DXA provides measures of lean mass which may be influenced by body compartments other than skeletal muscle, the relevance of this diagnostic cutoff point is uncertain. Furthermore, the study utilized a control group composed of patients affected by non-inflammatory rheumatic disorders as opposed to healthy controls, further limiting the relevance of applied cutoff points. In addition to the aforementioned uncertainties of establishing and applying normal values for components of body composition, it also is unclear how a single measure of body composition would be used in patient management. Studies discussing appropriate use and determination of DXA-derived lean mass cutoffs for sarcopenia in various populations of patients and underlying disorders continue to be featured in the literature.^{27,28}

Clinically Useful

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, or more effective therapy, or avoid unnecessary therapy, or avoid unnecessary testing.

Direct Evidence

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

No RCTs were identified to support the utility of DXA for this indication.

Chain of Evidence

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

Pooled analyses indicate that there is generally strong correlation between estimates of FM as assessed by DXA versus CT or MRI, particularly in populations with clinical conditions for which risk of adverse outcomes associated with visceral adiposity may be of particular importance.⁴ In a broader population, including healthy individuals, while there remains a strong overall correlation between these methods of FM estimation, significant variability suggests that there are some subpopulations in whom DXA may perform poorly as an estimate of adiposity compared to CT or MRI.³ A chain of evidence can be constructed supporting DXA as a clinically valid method of evaluating FM in individuals with certain clinical conditions, such as cardiovascular disease or chronic kidney disease. However, limited and heterogeneous evidence does not allow for extension of this chain of evidence to the population at large. Additionally, there is a lack of evidence to indicate that evaluation of body composition via DXA changes clinical management.

Section Summary: Dual-energy X-ray Absorptiometry as a Test to Detect Abnormal Body Composition

The available evidence was generated primarily in research settings and often used DXA body composition studies as a reference standard; these studies do not permit conclusions about the accuracy of DXA for measuring body composition. Systematic reviews with meta-analyses exploring the clinical validity of DXA measurements against reference methods for the quantification of FM indicate strong overall agreement between these modalities, but raise concerns regarding precision and reliability in some populations, particularly those without existing clinical conditions for which risk of adverse outcomes is influenced by abnormal visceral adiposity. Additionally, no studies were identified in which DXA body composition measurements were actively used in patient management.

DUAL-ENERGY X-RAY ABORPTIOMETRY AS A TEST TO MONITOR CHANGES IN BODY COMPOSITION

Clinical Context and Test Purpose

The purpose of serial DXA body composition studies in individuals who have a clinical condition managed by monitoring body composition changes over time is to improve disease management.

The following PICO was used to select literature to inform this review.

Populations

The relevant population of interest is individuals with clinical conditions managed by monitoring body composition changes over time.

Interventions

The test being considered is serial DXA body composition studies.

Comparators

The following practices are currently being used to make decisions in this group: standard of care without DXA or an alternative method of body composition analysis.

Outcomes

The general outcomes of interest include symptom management and change in disease status. For individuals with anorexia nervosa, outcomes of interest would include disease-related morbidity, disease-related mortality, and rate of remission.

Study Selection Criteria

See information under the first indication.

Clinically Valid

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

The ability to detect a change in body composition over time is related in part to the precision of the technique, defined as the degree to which repeated measurements of the same variable give the same value. For example, DXA measurements of bone mass are thought to have a precision error of 1% to 3% and, given the slow rate of change in BMD in postmenopausal women treated for osteoporosis, it is likely that DXA scans would only be able to detect a significant change in BMD in the typical patient after 2 years of therapy. Of course, changes in body composition are anticipated to be larger and more rapid than changes in BMD in postmenopausal women; therefore, precision errors in DXA scans become less critical in interpreting results. However, precision errors for other body compartments such as lean and fat mass may differ and impact clinical validity. Coefficients of variation as high as 42.2% have been reported for fat mass.²⁹

REVIEW OF EVIDENCE

Prospective Studies

Several studies have reported on DXA measurement of body composition changes over time in clinical populations; none of these studies used DXA findings to make patient management decisions and few addressed how serial body composition assessment might improve health outcomes.^{29,30,31,32,33,34,35} A long-term prospective study assessing the association between body fat and BMI) was published by Iyengar et al (2019), featuring the ad hoc secondary analysis of results from the Women's Health Initiative RCT and observational study cohorts.³² Women (N=3460) were assessed at baseline and during years 1, 3, 6, and 9 for BMI and via DXA. Multivariable-adjusted hazard ratios (HR) for the association of various body fat measures with the risk of developing invasive or estrogen receptor positive (ER+) breast cancer were reported. Median follow-up duration was 16.9 years. Characteristics and results of clinical validity for breast cancer risk assessment are summarized in Tables 3 and 4.

Table 3. Study Characteristics of Clinical Validity of Risk Assessment

Study	Study Population	Design ^a	Reference Standard	Timing of Reference and Index Tests	Blinding of Assessors	Comment ^b
Iyengar et al (2019) ³²	Postmenopausal women aged 50 to 79 years enrolled in the Women's Health Initiative (WHI) RCT or observational study were considered for study. Women from 3 WHI trial centers were assessed longitudinally for body fat composition. Data from women with normal BMIs were assessed for correlations with breast cancer outcomes.	Prospective, sample selection NR	Clinical outcomes were confirmed via questionnaires. Breast cancer cases were confirmed via review of medical records and pathology reports.	NR	NR	Risk outcomes for women in the RCT and observational cohorts were not analyzed separately. Given that treatments utilized in the RCT group may have had an impact on breast cancer risk and outcomes, the relevance and utility of this study is uncertain.

BMI: body mass index; NR: not reported; RCT: randomized controlled trial.
^aNote 2 aspects of design: prospective, retrospective or nonconcurrent prospective and sample selection random or consecutive
^bNote other characteristics that could cause bias or limit relevance such as timeframe or practice setting.

Table 4. Clinical Validity of Breast Cancer Risk Assessment with DXA

Study; Subgroup; Body Fat DXA Measurement (Cutoff)	Initial N	Final N Cases/ Person - Years	Excluded Samples	Prevalence of Condition	Clinical Validity Outcome: Multivariable Adjusted HR (95% CI)				
					Baseline Body Fat Measures			Serial Body Fat Measures	
Iyengar et al (2019) ³² Invasive Breast Cancer	3464*	3460	4*	182	Highest Quartile	P-value for trend	Per 5-unit increase	Cutoff	Time-Dependent
Whole-body fat mass, kg (>25.1)	NR	NR	NR	57	1.89 (1.21-2.95)	0.004	1.28 (1.10-1.49)	≥ 22.1	1.43 (1.06-1.93)
Whole-body fat, % (>41.3)	NR	NR	NR	52	1.79 (1.14-2.83)	0.03	1.19 (1.03-1.37)	≥38.0	1.45 (1.07-1.95)
Fat mass of trunk, kg (>11.4)	NR	NR	NR	50	1.88 (1.18-2.98)	0.002	1.46 (1.14-1.87)	≥ 9.4	1.50 (1.12-2.03)
Ratio of trunk fat mass to mean of legs (>2.6)	NR	NR	NR	43	1.30 (0.83-2.02)	0.10	NR	NR	NR
Iyengar et al (2019) ³² ER+ Breast Cancer	3464	3460	4*	146	Highest Quartile	P-value for trend	Per 5-unit increase	Cutoff	Time-Dependent
Whole-body fat mass, kg (>25.1)	NR	NR	NR	48	2.21 (1.23-3.67)	0.002	1.35 (1.14-1.60)	≥22.1	1.41 (1.01-1.97)
Whole-body fat, % (>41.3)	NR	NR	NR	44	2.17 (1.29-3.66)	0.01	1.27 (1.08-1.48)	≥38.0	1.50 (1.07-2.10)
Fat mass of trunk, kg (>11.4)	NR	NR	NR	41	1.98 (1.18-3.31)	0.003	1.56 (1.18-2.06)	≥9.4	1.46 (1.05-2.04)
Ratio of trunk fat mass to mean of legs (>2.6)	NR	NR	NR	34	1.28 (0.78-2.10)	0.13	NR	NR	NR

CI: confidence interval; DXA: dual-energy x-ray absorptiometry; ER+: estrogen receptor-positive; HR: hazard ratio; NR: not reported.

* Excluded cases were lost to follow-up with ER+ status not reported.

These results suggest that standard BMI categorization may be inadequate for the risk assessment of invasive breast cancers in postmenopausal women. However, the clinical utility of DXA findings on patient management protocols and health outcomes requires further study.

Arthur et al (2020) published additional results from the Women's Health Initiative cohort of postmenopausal women (N=10,931), reporting additional associations between DXA-derived measures of body fat and breast cancer risk.³⁶ The multivariable-adjusted HR for risk of invasive breast cancer per standard deviation (SD) increase in trunk fat mass was 1.21 (95% CI, 1.12 to 1.31) and whole body fat mass was 1.21 (95% CI, 1.12 to 1.30). The multivariable-adjusted HR for risk of ER+ breast cancer per SD increase in trunk fat mass was 1.21 (95% CI, 1.11 to 1.31) and whole body fat mass was 1.22 (95% CI, 1.11 to 1.33). Multivariable-adjusted HR for invasive breast cancer per SD increase in BMI was also significant, with a HR 1.19 (95% CI, 1.10 to 1.28). Trends of time-dependent analyses of anthropometric measures and overall ER+ incident breast cancer cases were significant for BMI (P < 0.001) and waist circumference (P < 0.001). Therefore, the added clinical utility of DXA-derived fat measures is unclear for this population.

Relevance and study design and conduct limitations are summarized in Tables 5 and 6.

Table 5. Study Relevance Limitations

Study	Population ^a	Intervention ^b	Comparator ^c	Outcomes ^d	Duration of Follow-Up ^e
Arthur et al (2020) ³⁶	1. Study population is unclear	2. Version used unclear regarding both DXA and patient participation in RCT treatment or observational groups.	3. Not compared to other tests used for same purpose.	3,5. Key clinical validity outcomes not reported; adverse events of the test not described	
Iyengar et al (2019) ³²	1, 4. Study population is unclear; study population not representative of intended use.	2. Version used unclear regarding both DXA and patient participation in RCT treatment or observational groups.	3. Not compared to other tests used for same purpose.	3, 5. Key clinical validity outcomes not reported; adverse events of the test not described.	

DXA: dual-energy x-ray absorptiometry; RCT: randomized controlled trial.

The study limitations stated in this table are those notable in the current review, this is not a comprehensive gaps assessment.

^a Population key: 1. Intended use population unclear; 2. Clinical context is unclear; 3. Study population is unclear; 4. Study population not representative of intended use.

^b Intervention key: 1. Classification thresholds not defined; 2. Version used unclear; 3. Not intervention of interest.

^c Comparator key: 1. Classification thresholds not defined; 2. Not compared to credible reference standard; 3. Not compared to other tests in use for same purpose.

^d Outcomes key: 1. Study does not directly assess a key health outcome; 2. Evidence chain or decision model not explicated; 3. Key clinical validity outcomes not reported (sensitivity, specificity, and predictive values); 4. Reclassification of diagnostic or risk categories not reported; 5. Adverse events of the test not described (excluding minor discomforts and inconvenience of venipuncture or noninvasive tests).

^e Follow-Up key: 1. Follow-up duration not sufficient with respect to natural history of disease (true-positives, true-negatives, false-positives, false-negatives cannot be determined).

Table 6. Study Design and Conduct Limitations

Study	Selection ^a	Blinding ^b	Delivery of Test ^c	Selective Reporting ^d	Data Completeness ^e	Statistical ^f
Arthur et al (2020) ³⁶	1. Selection not described.	1. Blinding not described.	1, 4. Timing of delivery of index or reference tests not clear; expertise of evaluators not described.	2. Evidence of selective reporting (covariates did not have to be prespecified).		
Iyengar et al (2019) ³²	1. Selection not described.	1. Blinding not described.	1, 4. Timing of delivery of index or reference tests not clear; expertise of evaluators not described.	2. Evidence of selective reporting (covariates did not have to be prespecified).	1. Inadequate description of indeterminate and missing samples.	2. Comparison with other tests not reported.

The study limitations stated in this table are those notable in the current review, this is not a comprehensive gaps assessment.

^a Selection key: 1. Selection not described; 2. Selection not random or consecutive (ie, convenience).

^b Blinding key: 1. Not blinded to results of reference or other comparator tests.

^c Test Delivery key: 1. Timing of delivery of index or reference test not described; 2. Timing of index and comparator tests not same; 3. Procedure for interpreting tests not described; 4. Expertise of evaluators not described.

^d Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.

^e Data Completeness key: 1. Inadequate description of indeterminate and missing samples; 2. High number of samples excluded; 3. High loss to follow-up or missing data.

^f Statistical key: 1. Confidence intervals and/or p values not reported; 2. Comparison with to other tests not reported.

Clinically Useful

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, or more effective therapy, or avoid unnecessary therapy or testing.

Direct Evidence

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

No RCTs were identified to support the utility of DXA for this indication.

Chain of Evidence

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

Because the clinical validity of DXA for this population cannot be established, a chain of evidence cannot be constructed.

Section Summary: Dual-energy X-ray Absorptiometry as a Test to Monitor Changes in Body Composition

Studies assessing DXA used it as a tool to measure body composition and were not designed to assess the accuracy of DXA. None of the studies used DXA findings to make patient management decisions or addressed how serial body composition assessment might improve health outcomes.

BIOIMPEDANCE AS A TEST TO DETECT ABNORMAL BODY COMPOSITION

Talma et al (2013) performed a review of 50 studies to assess validity, responsiveness, reliability and measurement error of bioelectrical impedance analysis (BIA) in estimating percent body fat in children and adolescents.³⁷ There was strong evidence for good reliability. However, test-retest mean differences ranges from 7.5% to 13.4% of total percent body fat in the included study samples, indicating considerable measurement error. The review suggested that BIA is a practical method to estimate percent body fat in children and adolescents; however, noted that validity and measurement error are not satisfactory.

Haverkort et al (2015) performed a systematic review to explore the variability of empirical prediction equations used in BIA estimations and to evaluate the validity of BIA estimations in adult surgical and oncological patients.³⁸ The reviewers found that BIA underestimated the total body water and fat free mass; and, estimates of the fat mass demonstrated large variability. The reviewers concluded that application of equations validated in healthy subjects to predict body composition is not as accurate in this population. They recommended that BIA estimations can only be useful when performed longitudinally and under the same conditions.

Section Summary: Bioimpedance to Detect Abnormal Body Composition

The peer reviewed medical literature does not support that BIA is a reliable indicator of body composition. Also, no studies have been identified in which BIA measurements were actively used in patient management. The evidence is insufficient to determine the effects of the technology on net health outcomes.

SUMMARY OF EVIDENCE

For individuals who have a clinical condition associated with abnormal body composition who receive dual-energy x-ray absorptiometry (DXA) body composition studies, the evidence includes systematic reviews and several cross-sectional studies comparing DXA with other techniques. Relevant outcomes are symptoms and change in disease status. The available studies were primarily conducted in research settings and often used DXA body composition studies as a reference standard; Systematic reviews with meta-analyses exploring the clinical validity of DXA measurements against reference methods for the quantification of fat mass indicate strong overall agreement between these modalities, but raise concerns for precision and reliability in some populations, particularly those without existing clinical conditions for which risk of adverse outcomes is influenced by abnormal visceral adiposity. More importantly, no studies were identified in which DXA body composition measurements were actively used in patient management. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have a clinical condition managed by monitoring changes in body composition over time who receive serial DXA body composition studies, the evidence includes several prospective studies monitoring patients over time. Relevant outcomes are symptoms and change in disease status. The studies used DXA as a tool to measure body composition and were not designed to assess the accuracy of DXA. None of the studies used DXA findings to make patient management decisions or addressed how serial body composition assessment might improve health outcomes. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For the use of bioelectrical impedance analysis in determining body composition, there are no studies identified in which BIA measurements were actively used in patient management. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

SUPPLEMENTAL INFORMATION

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American Association of Clinical Endocrinology et al

The American Association of Clinical Endocrinology (AACE) and American College of Endocrinology (ACE) clinical practice guideline on obesity was updated in 2016.³⁹ Table 7 describes relevant recommendations for the diagnosis of overweight and obesity from the AACE/ACE guideline. The authors also state that "The DEXA [dual x-ray absorptiometry] scan also allows for calculation of the fat mass index (total body fat mass [kg] divided by height [m²]), which is a physiologic relevant measure of adiposity. The clinical utility of these measures is limited by availability, cost, and lack of outcomes data, but they have been applied extensively in research settings. Body fat percentage cut points for obesity have been proposed by the World Health Organization (WHO) to be 25% for men and 35% for women."

Table 7. American Association of Clinical Endocrinology/American College of Endocrinology Recommendations for Diagnosis of Overweight and Obesity

Recommendation	Quality of evidence ^a	Grade of recommendation ^b
All adults should be screened annually using a BMI measurement; in most populations a cutoff point of ≥ 25 kg/m ² should be used to initiate further evaluation of overweight or obesity.	2 (upgraded due to high relevance)	A
BMI should be used to confirm an excessive degree of adiposity and to classify individuals as having overweight (BMI 25 to 29.9 kg/m ²) or obesity (BMI ≥ 30 kg/m ²), after taking into account age, gender, ethnicity, fluid status, and muscularity; therefore, clinical evaluation and judgment must be used when BMI is employed as the anthropometric indicator of excess adiposity, particularly in athletes and those with sarcopenia.	2 (upgraded due to high relevance)	A

When evaluating patients for adiposity-related disease risk, WC should be measure in all patients with BMI <35 kg/m ² .	2 (upgraded due to high relevance)	A
In many populations, a WC cutoff point of ≥94 cm in men and ≥80 cm in women should be considered at risk and consistent with abdominal obesity; in the U.S. and Canada, cutoff points that can be used to indicate increased risk are ≥102 cm for men and ≥88 cm for women.	2 (upgraded due to high relevance)	A
Other measurements of adiposity (e.g., bioelectric impedance, air/water displacement plethysmography, or dual-energy X-ray absorptiometry [DEXA]) may be considered at the clinician's discretion if BMI and physical examination results are equivocal or require further evaluation.	2 (downgraded due to evidence gaps)	C
However, the clinical utility of these measures [listed in the above recommendation] is limited by availability, cost, and lack of outcomes data for validated cutoff points.	2	B

BMI: body mass index; WC: waist circumference.

^aEvidence quality 2 indicates intermediate-level evidence, including meta-analyses of nonrandomized prospective or case-controlled trials, nonrandomized controlled trials, prospective cohort studies, and/or retrospective case-control studies.

^bGrade A, B, and C indicate strong, intermediate, and weak recommendations, respectively.

American College of Radiology et al

The American College of Radiology (ACR), the Society for Pediatric Radiology (SPR), and the Society of Skeletal Radiology (SRR) (2018) issued a collaborative practice parameter to assist practitioners in providing appropriate radiologic care for their patients.⁴⁰ Dual-energy absorptiometry (DXA) was described as a "clinically proven, accurate and reproducible method of measuring bone mineral density (BMD) in the lumbar spine, proximal femur, forearm, and whole body," that "may also be used to measure whole-body composition, including nonbone lean mass (LM) and fat mass (FM)." DXA measurement of BMD, LM, or FM is indicated whenever a clinical decision is likely to be directly influenced by the test result. In particular, LM and FM may be useful in assessing conditions such as sarcopenia and cachexia. Specifically, DXA may be indicated as a tool for the measurement of regional and whole body FM and LM in patients afflicted with conditions such as malabsorption, cancer, or eating disorders.

American Society for Parenteral and Enteral Nutrition

The American Society for Parenteral and Enteral Nutrition (ASPEN) published clinical guidelines on the validity of body composition assessment in clinical populations in 2019, as a complement to the Global Leadership Initiative on Malnutrition (GLIM) criteria for malnutrition (described below).⁴ The systematic review with meta-analysis used to develop these guidelines is described above. The target population of the guideline was adults "with a potentially inflammatory condition or pathological end point associated with a specific disease or clinical condition such as cancer, cardiovascular disease (CVD), cardiac failure, diabetes, hepatic or renal disease, human immunodeficiency virus, or possessing a condition that requires surgical intervention." The target population did not include healthy individuals or those with obesity, except when "linked to a clinical condition such as metabolic syndrome, hypertension, etc." Studies evaluated for guideline development involved specific body composition assessment methodologies (DXA, bioelectrical impedance analysis, or ultrasound) and were required to use a more precise comparator; for studies evaluating DXA, these included computed tomography, magnetic resonance imaging, or multicompartiment

models. Anthropometric measurements "were not included since these are considered surrogate measures of body composition." Table 8 describes relevant recommendations from the ASPEN guideline.

Table 8. American Society for Parenteral and Enteral Nutrition Clinical Guideline Recommendations for Body Composition Assessment in Adult Clinical Populations

Recommendation	Quality of evidence	Strength of recommendation
We recommend the use of DXA for assessing fat mass in patients with clinical conditions.	Low	Strong
No recommendation can be made at this time to support the use of ultrasound in a clinical setting for assessing body composition.	Very low	Weak
No recommendations can be made regarding the validity of using bioelectrical impedance analysis in clinical populations.	Low	Weak

DXA: dual-energy x-ray absorptiometry

Global Leadership Initiative on Malnutrition

The GLIM, representing ASPEN and several international professional clinical nutrition societies, was created at the ASPEN annual meeting in 2016 with the charge of reaching global consensus on core diagnostic criteria for malnutrition in adults. The resulting GLIM criteria were published in 2018.⁴¹ An adult who is determined to be at risk of malnutrition (based on validated screening tools) should then be assessed for phenotypic (including non-volitional weight loss, low body mass index, and/or reduced muscle mass) and etiologic diagnostic criteria (reduced food intake or assimilation and/or disease burden or inflammatory condition) for malnutrition. A diagnosis of malnutrition constitutes meeting at least 1 phenotypic criterion and 1 etiologic criterion. The reduced muscle mass phenotypic criterion is defined by validated body composition measurement techniques; recommended thresholds defining reduced muscle mass are described in Table 9. Validated methods of measuring muscle mass recommended by GLIM include "dual-energy absorptiometry or other validated body composition measures such as bioelectrical impedance, ultrasound, computer tomography or magnetic resonance imaging." Because these modalities are not widely available on a global scale, the authors further state: "Physical examination or anthropometric measures of calf or arm muscle circumference are therefore included as alternative measures."

Table 9. Global Leadership Initiative on Malnutrition Recommended Thresholds for Reduced Muscle Mass

Muscle mass measurement	Threshold for males	Threshold for females
ASMI, kg/m ²	<7.26	<5.25
ASMI, kg/m ² (older adults)	<7	<6
ASMI, kg/m ² (Asian individuals)		
DXA	<7	<5.4
BIA	<7	<5.7
FFMI, kg/m ²	<17	<15
ALM, kg	<21.4	<14.1

BMI-adjusted ALM (ALM/BMI)	<0.725	<0.591
----------------------------	--------	--------

ALM: appendicular lean mass; ASMI: appendicular skeletal muscle index; BIA: bioelectrical impedance analysis; BMI: body mass index; DXA: dual x-ray absorptiometry; FFMI: fat free mass index.

International Society for Clinical Densitometry

The International Society for Clinical Densitometry (2019) statements on the use of DXA for body composition.⁴² Use of DXA for measurement of body composition was suggested for use in the following clinical conditions:

- To assess fat distribution in patients living with human immunodeficiency virus (HIV) who are using anti-retroviral agents known to increase the risk of lipoatrophy.
- To assess fat and lean mass changes in obese patients undergoing bariatric surgery (or medical, diet, or weight loss regimens with anticipated large weight loss) when weight loss exceeds approximately 10%. The statement noted that the impact of DXA studies on clinical outcomes in these patients is uncertain.
- To assess fat and lean mass in patients with muscle weakness and poor physical functioning. The impact on clinical outcomes is uncertain.

Of note, pregnancy is a contraindication to use of DXA to measure body composition. The statement also adds that the clinical utility of DXA measurements of adiposity and lean mass (eg, visceral adipose tissue, lean mass index, fat mass index) is uncertain. Furthermore, while the use of DXA adiposity measures such as fat mass index may be useful in risk-stratifying patients for cardio-metabolic outcomes, specific thresholds to define obesity have not been established.

U.S. Preventive Services Task Force Recommendations

No U.S. Preventive Services Task Force recommendations for whole-body DXA have been identified.

Ongoing and Unpublished Clinical Trials

Some currently unpublished trials that might influence this review are listed in Table 10.

Table 10. Summary of Key Trials

NCT Number	Trial Name	Planned Enrollment	Completion Date
<i>Ongoing</i>			
NCT03621306	Precision and Reliability of Dual X-ray Absorptiometry (DXA) Testing	400	Aug 2028
NCT05639556	Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF	300	Dec 2028
NCT05879692	Response of Irritable Bowel Syndrome to Abdominal Fat Reduction	60	Dec 2023
NCT05699863	A Multidisciplinary Approach to Screening for Obesity Complications - The MULTISITE Study	90	Jan 2036
NCT05885672	A Multi-Modal Approach to Improving the Early Detection of Cardiometabolic Disease Risk	200	July 2024

NCT: national clinical trial

^a Denotes industry-sponsored or cosponsored trial.

Government Regulations

National:

There is no national coverage determination on this topic.

Local:

There is no local coverage determination on this topic.

Wisconsin Physicians Service Insurance Corporation

Local Coverage Article: Billing and Coding: Category III Codes (A56902)

Original effective date: 08/29/2019

Revision effective date: 08/29/2024

Code 0358T is not listed as a reasonable and medically necessary code.

(The above Medicare information is current as of the review date for this policy. However, the coverage issues and policies maintained by the Centers for Medicare & Medicare Services [CMS, formerly HCFA] are updated and/or revised periodically. Therefore, the most current CMS information may not be contained in this document. For the most current information, the reader should contact an official Medicare source.)

Related Policies

- Bioelectrical Impedance for Body Composition Analysis (Retired)
- Bone Density Studies (Retired)

References

1. Borga M, West J, Bell JD, et al. Advanced body composition assessment: from body mass index to body composition profiling. J Investig Med. Jun 2018; 66(5): 1-9. PMID 29581385
2. Barone M, Losurdo G, Iannone A, et al. Assessment of body composition: Intrinsic methodological limitations and statistical pitfalls. Nutrition. Oct 2022; 102: 111736. PMID 35810580
3. Murphy J, Bacon SL, Morais JA et al. Intra-Abdominal Adipose Tissue Quantification by Alternative Versus Reference Methods: A Systematic Review and Meta-Analysis. Obesity (Silver Spring). Jul 2019;27(7). PMID 31131996
4. Sheean P, Gonzalez MC, Prado CM et al. American Society for Parenteral and Enteral Nutrition Clinical Guidelines: The Validity of Body Composition Assessment in Clinical Populations. JPEN J Parenter Enteral Nutr. Jan 2020;44(1):12-43. PMID 31216070
5. Calella P, Valerio G, Brodlie M et al. Tools and Methods Used for the Assessment of Body Composition in Patients With Cystic Fibrosis: A Systematic Review. Nutr Clin Pract. Oct 2019;34(5):701-714. PMID 30729571
6. Calella P, Valerio G, Brodlie M et al. Cystic fibrosis, body composition, and health outcomes: a systematic review. Nutrition. Nov 2018;55-56:131-139. PMID 29981489
7. Bundred J, Kamarajah SK, Roberts KJ. Body composition assessment and sarcopenia in patients with pancreatic cancer: a systematic review and meta-analysis. HPB (Oxford). Dec 2019;21(12):163-1612. PMID 31266698
8. Alves FD, Souza GC, Biolo A, et al. Comparison of two bioelectrical impedance devices and dual-energy X-ray absorptiometry to evaluate body composition in heart failure. J Hum Nutr Diet. Dec 2014;27(6):632-8. PMID 24684316
9. Ziai S, Coriati A, Chabot K, et al. Agreement of bioelectric impedance analysis and dual-energy X-ray absorptiometry for body composition evaluation in adults with cystic fibrosis. J Cyst Fibros. Sep 2014;13(5):585-588. PMID 24522087

10. Elkan AC, Engvall IL, Tengstrand B et al. Malnutrition in women with rheumatoid arthritis is not revealed by clinical anthropometrical measurements or nutritional evaluation tools. *Eur J Clin Nutr.* Oct 2008; 62(10):1239-47. PMID 17637600
11. Jensky-Squires NE, Dieli-Conwright CM, Rossuello A et al. Validity and reliability of body composition analysers in children and adults. *Br J Nutr.* Oct 2008; 100(4):859-65. PMID 18346307
12. Kullberg J, Brandberg J, Angelhed JE et al. Whole-body adipose tissue analysis: comparison of MRI, CT and dual energy X-ray absorptiometry. *Br J Radiol.* Feb 2009; 82(974):123-30. PMID 19168691
13. Liem ET, De Lucia Rolfe E, L'Abée C et al. Measuring abdominal adiposity in 6 to 7-year-old children. *Eur J Clin Nutr.* Jul 2009; 63(7):835-41. PMID 19127281
14. Bedogni G, Agosti F, De Col A, et al. Comparison of dual-energy X-ray absorptiometry, air displacement plethysmography and bioelectrical impedance analysis for the assessment of body composition in morbidly obese women. *Eur J Clin Nutr.* Nov 2013;67(11):1129-1132. PMID 24022260
15. Monteiro PA, Antunes Bde M, Silveira LS, et al. Body composition variables as predictors of NAFLD by ultrasound in obese children and adolescents. *BMC Pediatr.* Jan 29 2014;14:25. PMID 24476029
16. Tompuri TT, Lakka TA, Hakulinen M, et al. Assessment of body composition by dual-energy X-ray absorptiometry, bioimpedance analysis and anthropometrics in children: the Physical Activity and Nutrition in Children study. *Clin Physiol Funct Imaging.* Jan 2015;35(1):21-33. PMID 24325400
17. Alves Junior CAS, de Lima LRA, de Souza MC et al. Anthropometric measures associated with fat mass estimation in children and adolescents with HIV. *Appl Physiol Nutr Metab.* May 2019;44(5):493-498. PMID 30286302
18. Barr RD, Inglis D, Athale U, et al. The Influence of Body Composition on Bone Health in Long-term Survivors of Acute Lymphoblastic Leukemia in Childhood and Adolescence: Analyses by Dual-energy X-ray Absorptiometry and Peripheral Quantitative Computed Tomography. *J Pediatr Hematol Oncol.* Apr 27 2022. PMID 35482464
19. Chang CC, Chen YK, Chiu HC, et al. Assessment of Sarcopenia and Obesity in Patients with Myasthenia Gravis Using Dual-Energy X-ray Absorptiometry: A Cross-Sectional Study. *J Pers Med.* Nov 03 2021; 11(11). PMID 34834491
20. Smoot BJ, Mastick J, Shepherd J, et al. Use of Dual-Energy X-Ray Absorptiometry to Assess Soft Tissue Composition in Breast Cancer Survivors With and Without Lymphedema. *Lymphat Res Biol.* Nov 18 2021. PMID 34793255
21. Dandache C, Confavreux CB, Gavaille A, et al. Peripheral but not axial muscle mass is associated with early mortality in bone metastatic lung cancer patients at diagnosis. *Joint Bone Spine.* Jul 11 2023; 90(5): 105613. PMID 37442335
22. Wang LH, Leung DG, Wagner KR, et al. Lean tissue mass measurements by dual-energy X-ray absorptiometry and associations with strength and functional outcome measures in facioscapulohumeral muscular dystrophy. *Neuromuscul Disord.* Jun 21 2023. PMID 37400350
23. Dawra S, Gupta P, Yadav N, et al. Association between the Distribution of Adipose Tissue and Outcomes in Acute Pancreatitis: A Comparison of Methods of Fat Estimation. *Indian J Radiol Imaging.* Jan 2023; 33(1): 12-18. PMID 36855725
24. Woolcott OO, Bergman RN. Defining cutoffs to diagnose obesity using the relative fat mass (RFM): Association with mortality in NHANES 1999-2014. *Int J Obes (Lond).* Jun 2020; 44(6): 1301-1310. PMID 31911664
25. Staunstrup LM, Nielsen HB, Pedersen BK, et al. Cancer risk in relation to body fat distribution, evaluated by DXA-scans, in postmenopausal women - the Prospective Epidemiological Risk Factor (PERF) study. *Sci Rep.* Mar 29 2019; 9(1): 5379. PMID 30926844

26. Reina D, Gómez-Vaquero C, Díaz-Torné C et al. Assessment of nutritional status by dual X-Ray absorptiometry in women with rheumatoid arthritis: A case-control study. *Medicine (Baltimore)*. Feb 2019;98(6):e14361. PMID 30732168
27. Sinclair M, Hoermann R, Peterson A et al. Use of Dual X-ray Absorptiometry in men with advanced cirrhosis to predict sarcopenia-associated mortality risk. *Liver Int.*, 2019 Feb 13;39(6). PMID 30746903
28. Lindqvist C, Brismar TB, Majeed A et al. Assessment of muscle mass depletion in chronic liver disease: Dual-energy x-ray absorptiometry compared with computed tomography. *Nutrition*. May 2019 1;61:93-98. PMID 30703575
29. Dordevic AL, Bonham M, Ghasem-Zadeh A et al. Reliability of Compartmental Body Composition Measures in Weight-Stable Adults Using GE iDXA: Implications for Research and Practice. *Nutrients*. Oct 12 2018;10(10). PMID 30321991
30. Bazzocchi A, Ponti F, Cariani S, et al. Visceral Fat and Body Composition Changes in a Female Population After RYGBP: a Two-Year Follow-Up by DXA. *Obes Surg*. Mar 2015;25(3):443-51. PMID 25218013
31. Franzoni E, Ciccarese F, Di Pietro E, et al. Follow-up of bone mineral density and body composition in adolescents with restrictive anorexia nervosa: role of dual-energy X-ray absorptiometry. *Eur J Clin Nutr*. Feb 2014;68(2):247-252. PMID 24346474
32. Iyengar NM, Arthur R, Manson JE et al. Association of Body Fat and Risk of Breast Cancer in Postmenopausal Women With Normal Body Mass Index: A Secondary Analysis of a Randomized Clinical Trial and Observational Study. *JAMA Oncol*. Feb 01 2019;5(2):155-163. PMID 30520976
33. Ashby-Thompson M, Heshka S, Rizkalla B, et al. Validity of dual-energy x-ray absorptiometry for estimation of visceral adipose tissue and visceral adipose tissue change after surgery-induced weight loss in women with severe obesity. *Obesity (Silver Spring)*. May 2022; 30(5): 1057-1065. PMID 35384351
34. Sherlock SP, Palmer J, Wagner KR, et al. Dual-energy X-ray absorptiometry measures of lean body mass as a biomarker for progression in boys with Duchenne muscular dystrophy. *Sci Rep*. Nov 05 2022; 12(1): 18762. PMID 36335191
35. Nguyen AL, Herath M, Burns M, et al. The value of whole-body dual-energy x-ray absorptiometry in assessing body composition in patients with inflammatory bowel disease: a prospective study. *Eur J Gastroenterol Hepatol*. Jan 01 2024; 36(1): 52-61. PMID 37942750
36. Arthur RS, Xue X, Kamensky V, et al. The association between DXA-derived body fat measures and breast cancer risk among postmenopausal women in the Women's Health Initiative. *Cancer Med*. Feb 2020; 9(4): 1581-1599. PMID 31875358
37. Talma H, Chinapaw JM, Bakker B, et al. Bioelectrical impedance analysis to estimate body composition in children and adolescents: a systematic review and evidence appraisal of validity, responsiveness, reliability and measurement error. *Obes Rev*. 2013; 14(11): 895-905.
38. Haverkort EB, Reijven PLM, Binnekade JM, et al. Bioelectrical impedance analysis to estimate body composition in surgical and oncological patients: a systematic review. *Eur J Clin Nutr*. 2015 Jan;69(1):3-13 PMID 25271012
39. Garvey WT, Mechanick JI, Brett EM, et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY. *Endocr Pract*. Jul 2016; 22 Suppl 3: 1-203. PMID 27219496
40. American College of Radiology. ACR-SPR-SSR Practice Parameter for the Performance of Dual-energy X-ray Absorptiometry (DXA). 2018; <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/DXA.pdf>. Accessed 9/27/23.

41. Jensen GL, Cederholm T, Correia MITD, et al. GLIM Criteria for the Diagnosis of Malnutrition: A Consensus Report From the Global Clinical Nutrition Community. JPEN J Parenter Enteral Nutr. Jan 2019; 43(1): 32-40. PMID 30175461
42. International Society for Clinical Densitometry. 2019 ISCD Official Positions – Adult. 2019. <https://iscd.org/learn/official-positions/adult-positions/> Accessed 9/24/24
43. Wisconsin Physicians Insurance Service Corporation. Local Coverage Article. Category III Codes (A56902). Original effective date: 08/29/2019. Revision effective date: 08/29/2024.

The articles reviewed in this research include those obtained in an Internet based literature search for relevant medical references through 9/24/24, the date the research was completed.

Joint BCBSM/BCN Medical Policy History

Policy Effective Date	BCBSM Signature Date	BCN Signature Date	Comments
12/8/05	12/9/05	12/1/05	Joint policy established
3/1/07	12/28/06	1/14/07	Routine maintenance
1/1/09	10/13/08	12/30/08	Routine maintenance
9/1/11	6/21/11	6/21/11	Routine maintenance. CPT code 0028T deleted; NOC code 76499 added
11/1/12	8/21/12	8/21/12	Routine maintenance
3/1/14	12/10/13	1/6/14	Routine maintenance
1/1/16	10/13/15	10/27/15	Routine maintenance
1/1/17	10/11/16	10/11/16	Routine maintenance
1/1/18	10/19/17	10/19/17	Routine maintenance
1/1/19	10/16/18	10/16/18	Routine maintenance
1/1/20	10/15/19		Routine maintenance
1/1/21	10/20/20		Routine maintenance Ref 16,17,25,26,28 added
11/1/21	8/17/21		Integrated IMP Bioelectrical Impedance for Body Composition Analysis. Ref 26, 27 added
3/1/22	12/14/21		Routine maintenance
3/1/23	12/20/22		Routine maintenance (jf) added references 16,17,18, 28, 35 Vendor: NA
3/1/24	12/19/23		Routine maintenance (jf) Vendor Managed: NA Added ref: 1,2,21,22,23,34,36,38
3/1/25	12/17/24		Routine maintenance (jf) Vendor Managed: NA Added ref: 35

Next Review Date: 4th Qtr, 2025

BLUE CARE NETWORK BENEFIT COVERAGE
POLICY: BODY COMPOSITION STUDIES – DUAL ENERGY X-RAY ABSORPTIOMETRY (DXA) AND BIOELECTRICAL IMPEDANCE

I. Coverage Determination:

Commercial HMO (includes Self-Funded groups unless otherwise specified)	Not covered.
BCNA (Medicare Advantage)	See Government Regulations section.
BCN65 (Medicare Complementary)	Coinsurance covered if primary Medicare covers the service.

II. Administrative Guidelines:

- The member's contract must be active at the time the service is rendered.
- Coverage is based on each member's certificate and is not guaranteed. Please consult the individual member's certificate for details. Additional information regarding coverage or benefits may also be obtained through customer or provider inquiry services at BCN.
- The service must be authorized by the member's PCP except for Self-Referral Option (SRO) members seeking Tier 2 coverage.
- Services must be performed by a BCN-contracted provider, if available, except for Self-Referral Option (SRO) members seeking Tier 2 coverage.
- Payment is based on BCN payment rules, individual certificate and certificate riders.
- Appropriate copayments will apply. Refer to certificate and applicable riders for detailed information.
- CPT - HCPCS codes are used for descriptive purposes only and are not a guarantee of coverage.